Literature DB >> 21332695

Psoriasis induced by cetuximab: a paradoxical adverse effect.

Albert Mas-Vidal1, Pablo Coto-Segura, Cristina Galache-Osuna, Jorge Santos-Juanes.   

Abstract

Cetuximab, an epidermal growth factor receptor inhibitor, is a chemotherapeutical agent featuring well-known adverse dermatological effects related to tumour-response prognosis. In psoriasis, the epidermal growth factor receptor is overexpressed; hence, the expectation would be that an epidermal growth factor receptor inhibitor could improve psoriatic lesions. We report a case of psoriasis induced by cetuximab, which was a surprising adverse effect.
© 2010 The Authors. Australasian Journal of Dermatology © 2010 The Australasian College of Dermatologists.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21332695     DOI： 10.1111/j.1440-0960.2010.00675.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN： 0004-8380            Impact factor:   2.875


  4 in total

1.  Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris.

Authors:  Ken Okamoto; Hiromichi Maeda; Takeo Shiga; Mai Shiga; Ken Dabanaka; Kazuhiro Hanazaki; Michiya Kobayashi
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 2.  Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Authors:  Maria Vastarella; Gabriella Fabbrocini; Vincent Sibaud
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

3.  A case of psoriasis pustolosa palmaris induced by cetuximab.

Authors:  Elena Marinello; Davide Pastorelli; Mauro Alaibac
Journal:  BMJ Case Rep       Date:  2016-03-18

Review 4.  The Immunogenetics of Psoriasis and Implications for Drug Repositioning.

Authors:  Xuan Xu; Hong-Yu Zhang
Journal:  Int J Mol Sci       Date:  2017-12-08       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.